# 急性细菌性皮肤结构感染市场 > 急性细菌性皮肤及皮肤结构感染市场研究报告按感染类型（蜂窝组织炎、丹毒、脓疱病、毛囊炎、脓肿）、按病原体（金黄色葡萄球菌、化脓性链球菌、铜绿假单胞菌、肠杆菌科、厌氧菌）、按治疗环境（门诊、住院、急诊科）、按作用机制（青霉素、头孢菌素、大环内酯类、林可胺类、氟喹诺酮类）、按给药途径（口服、静脉注射、局部用药）以及按地区（北美、欧洲、南美、亚太、中东和非洲） - 预测至2035年 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.44% - **2024:** $ 7.01 Billion - **2025:** $ 7.32 Billion - **2035:** $ 11.3 Billion - **Key Players:** AbbVie (US), Pfizer (US), Merck & Co. (US), Johnson & Johnson (US), GSK(GB), AstraZeneca (GB), Bayer (DE), Novartis (CH), Sanofi (FR) **Report ID:** MRFR/HC/29440-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** May 14, 2026 **URL:** https://www.marketresearchfuture.com/reports/acute-bacterial-skin-skin-structure-infection-market-31211 --- ## Market Summary ## **Acute Bacterial Skin and Skin Structure Infection Market Overview** As per MRFR analysis, the Foregut Surgery Device Market Size was estimated at 4.89 (USD Billion) in 2024. The Foregut Surgery Device Market Industry is expected to grow from 5.10 (USD Billion) in 2025 to 7.44 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 4.29% during the forecast period (2025 - 2034). ### **Key Acute Bacterial Skin and Skin Structure Infection Market Trends Highlighted** Antimicrobial resistance, the growing incidence of surgical site infections, and the expanding population of immunocompromised individuals with weakened immune systems are the most important market trends. These developments are anticipated to present lucrative possibilities in the global market for acute bacterial skin and skin structure infections in the coming years. Furthermore, expanded research and development activities, as well as the development of innovative treatments and therapies, are expected to drive market expansion. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Acute Bacterial Skin and Skin Structure Infection Market Drivers** ### **Growing Prevalence of Skin Infections** The increasing incidence of skin infections is a major factor driving the growth of the global acute bacterial skin and skin structure infection market. Skin infections are common worldwide, affecting individuals of all ages and socioeconomic backgrounds. Various factors contribute to the rise in skin infections, including the emergence of antibiotic-resistant bacteria, the growing population of immunocompromised individuals, and the increasing prevalence of chronic diseases such as diabetes and obesity. As the number of skin infections continues to rise, the demand for effective treatments, including antibiotics, antiseptics, and wound care products, is expected to increase, fueling the growth of the market. The rising prevalence of skin infections is particularly concerning in developing countries, where access to healthcare and sanitation may be limited. In these regions, skin infections can lead to severe complications and even death. The World Health Organization (WHO) estimates that skin infections account for approximately 10% of the global burden of disease, highlighting the significant impact of these infections on public health. To address the growing burden of skin infections, governments and healthcare organizations are implementing various strategies to improve prevention and treatment. These strategies include promoting hygiene practices, increasing access to antibiotics, and developing new and more effective treatments. The implementation of these strategies is expected to further drive the growth of the global acute bacterial skin and skin structure infection market in the coming years. ### **Rising Healthcare Expenditure** The increasing expenditure on healthcare is another key factor driving the growth of the global acute bacterial skin and skin structure infection market. Healthcare spending has been rising steadily in recent years due to factors such as the aging population, the growing prevalence of chronic diseases, and the introduction of new and expensive medical technologies. As healthcare expenditure continues to rise, the demand for medical products and services, including those used to treat skin infections, is expected to increase. The rising healthcare expenditure is particularly evident in emerging markets, where governments are investing heavily in improving healthcare infrastructure and access to medical care. This increased investment is leading to a growing demand for medical products and services, including those used to treat skin infections. The growing demand for medical products and services in emerging markets is expected to contribute to the growth of the global acute bacterial skin and skin structure infection market in the coming years. ### **Technological Advancements** The rapid pace of technological advancements in the healthcare industry is also driving the growth of the global acute bacterial skin and skin structure infection market. Technological advancements are leading to the development of new and more effective treatments for skin infections, as well as improved diagnostic tools and devices. These advancements are making it easier to diagnose and treat skin infections, which is leading to better patient outcomes and a reduced burden on the healthcare system. One of the most significant technological advancements in the treatment of skin infections is the development of new antibiotics. New antibiotics are being developed that are more effective against resistant bacteria, which is making it easier to treat skin infections that were once difficult to cure. Additionally, new diagnostic tools and devices are being developed that can help to identify the cause of a skin infection more quickly and accurately, which is leading to more targeted and effective treatment. ## **Acute Bacterial Skin and Skin Structure Infection Market Segment Insights:** ### **Acute Bacterial Skin and Skin Structure Infection Infection Type Insights** The global acute bacterial skin and skin structure infection market is segmented by Infection Type into Cellulitis, Erysipelas, [Impetigo](../../../reports/impetigo-market-30266), Folliculitis, and Abscess. Among these, Cellulitis held the largest market share of around 39.5% in 2023, and the market is expected to grow at a CAGR of 4.2% during the forecast period 2025-2034 The global acute bacterial skin and skin structure infection market for Cellulitis was valued at around USD 2.54 billion in 2023 and is expected to reach around USD 3.61 billion by 2032. The high prevalence of Cellulitis is attributed to factors such as the increasing incidence of skin injuries, surgical site infections, and the growing number of immunocompromised patients. Erysipelas, another common type of skin infection, accounted for a market share of approximately 22.1% in 2023. The market for Erysipelas is expected to grow at a CAGR of 4.5% during the forecast period, reaching a value of around USD 2.14 billion by 2032. Impetigo, a contagious skin infection caused by bacteria, held a market share of around 17.2% in 2023. The market for Impetigo is anticipated to grow at a CAGR of 4.3% during the forecast period, reaching a value of around USD 1.63 billion by 2032. Folliculitis, a skin infection that affects hair follicles, accounted for a market share of approximately 12.7% in 2023. The market for Folliculitis is expected to grow at a CAGR of 4.1% during the forecast period, reaching a value of around USD 1.21 billion by 2032. Abscess, a collection of pus beneath the skin, held a market share of around 8.5% in 2023. The market for Abscess is anticipated to grow at a CAGR of 4.0% during the forecast period, reaching a value of around USD 803.4 million by 2032. The growth of the market for acute bacterial skin and skin structure infections is driven by factors such as the rising prevalence of skin infections, increasing awareness of hygiene practices, and the growing adoption of advanced treatment options. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Acute Bacterial Skin and Skin Structure Infection Pathogen Insights** Staphylococcus aureus, Streptococcus pyogenes, Pseudomonas aeruginosa, Enterobacteriaceae, and Anaerobes are the major pathogens responsible for causing acute bacterial skin and skin structure infections (BSI). Staphylococcus aureus is the most common cause of ABSSSI, accounting for approximately 30% of cases. Streptococcus pyogenes is the second most common cause, accounting for approximately 20% of cases. Pseudomonas aeruginosa is a common cause of ABSSSI in hospitalized patients and immunocompromised individuals. Enterobacteriaceae and Anaerobes are less common causes of ABSSSI, but they can cause severe infections in certain populations. The increasing prevalence of skin and soft tissue infections, the rise in antibiotic resistance, and the growing demand for advanced treatment options are major factors driving the growth of the market. ### **Acute Bacterial Skin and Skin Structure Infection Treatment Setting Insights** The Treatment Setting segment of the global acute bacterial skin and skin structure infection market is segmented into Outpatient, Inpatient, and Emergency Departments. Among these segments, the Outpatient segment is expected to witness the fastest growth during the forecast period (2024-2032). The increasing preference for outpatient care due to lower costs, shorter wait times, and greater convenience is driving the growth of this segment. In 2023, the Outpatient segment accounted for a significant share of the global acute bacterial skin and skin structure infection market revenue. The growth of this segment can be attributed to the rising prevalence of skin and skin structure infections (SSSIs) and the increasing adoption of advanced treatment modalities in outpatient settings. Outpatient clinics and ambulatory surgical centers are becoming increasingly popular for the treatment of SSSIs due to their ability to provide timely and effective care. The Inpatient segment is also expected to experience steady growth during the forecast period. The increasing severity of SSSIs and the need for prolonged hospitalization are contributing to the growth of this segment. Hospitals provide a controlled environment for patients with severe infections to receive intensive care and monitoring. The Emergency Department segment is expected to account for a smaller share of the global acute bacterial skin and skin structure infection market revenue. However, this segment is expected to witness moderate growth during the forecast period due to the increasing number of patients seeking emergency care for SSSIs. Emergency departments play a crucial role in providing initial assessment and treatment to patients with skin infections before they are referred to appropriate outpatient or inpatient settings. ### **Acute Bacterial Skin and Skin Structure Infection Mechanism of Action Insights** The Mechanism of Action segment of the global acute bacterial skin and skin structure infection market is segmented into Penicillins, Cephalosporins, Macrolides, Lincosamides, and Fluoroquinolones. The Penicillins segment accounted for the largest share of the market in 2023 and is projected to continue to dominate the market over the forecast period. The Cephalosporins segment is expected to grow at the highest CAGR over the forecast period. The global acute bacterial skin and skin structure infection market is driven by the increasing prevalence of skin and soft tissue infections, the rising demand for effective and safe antibiotics, and the growing awareness of the importance of skin health. The market is also supported by the development of new and innovative antibiotics, as well as the increasing availability of generic drugs. The global acute bacterial skin and skin structure infection market is a highly competitive market with a number of major players. The key players in the market include Pfizer, GlaxoSmithKline, Johnson Johnson, Merck Co., and Novartis. These companies are investing heavily in research and development to develop new and innovative antibiotics, as well as to improve the efficacy and safety of existing antibiotics. ### **Acute Bacterial Skin and Skin Structure Infection Route of Administration Insights** The Global Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market is segmented into Oral, Intravenous, and Topical based on the Route of Administration. The market for Oral administration is expected to account for the largest share of the global ABSSSI Market in 2023, owing to the ease of administration and cost-effectiveness of oral medications. The Intravenous route of administration is preferred in severe cases where rapid drug delivery is required. The Topical route of administration is suitable for localized infections and is less likely to cause systemic side effects. The global acute bacterial skin and skin structure infection market for Oral administration is projected to grow at a CAGR of 4.2% during the forecast period (2024-2032). The Intravenous route of administration is expected to grow at a CAGR of 4.5% during the forecast period. The Topical route of administration is projected to grow at a CAGR of 4.8% during the forecast period. ### **Acute Bacterial Skin and Skin Structure Infection Regional Insights** The global acute bacterial skin and skin structure infection market is segmented into North America, Europe, APAC, South America, and MEA. The North American region is expected to hold the largest market share due to the high prevalence of skin infections and the increasing adoption of advanced treatment options. The European region is also expected to contribute significantly to the market growth, driven by the rising geriatric population and the increasing demand for advanced wound care products. The APAC region is expected to witness the fastest growth rate due to the increasing healthcare expenditure and the growing awareness about skin infections. The South American and MEA regions are also expected to contribute to the market growth, albeit at a slower pace. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Acute Bacterial Skin and Skin Structure Infection Market Key Players and Competitive Insights:** Major players in the acute bacterial skin and skin structure infection market are constantly engaged in research and development activities to enhance their product offerings and gain a competitive edge. Strategic collaborations and partnerships are also prevalent as companies seek to expand their geographic reach and access new markets. The acute bacterial skin and skin structure infection market is characterized by a diverse range of players, including multinational pharmaceutical companies, generic drug manufacturers, and specialty pharmaceutical companies focused on dermatology. Leading acute bacterial skin and skin structure infection market players are investing in innovative technologies, such as novel drug delivery systems and targeted therapies, to address unmet medical needs and improve patient outcomes. The acute bacterial skin and skin structure infection market development pipeline is robust, with several promising candidates in various stages of clinical development. These advancements are expected to further shape the competitive landscape and drive market growth in the coming years. Pfizer, a leading player in the acute bacterial skin and skin structure infection market, has a strong portfolio of antibiotics, including Zithromax and Vibramycin, which are widely used to treat bacterial skin infections. The company's focus on research and development has resulted in the development of new antibiotics, such as Sivextro, which has demonstrated efficacy against a broad spectrum of bacteria. Pfizer's global presence and strong distribution network enable it to reach a wide range of patients and healthcare providers. The company's commitment to innovation and patient care positions it well to maintain its leadership position in the acute bacterial skin and skin structure infection market. Merck, a global pharmaceutical company, is another major competitor in the acute bacterial skin and skin structure infection market. The company's antibiotic portfolio includes Cubicin, which is used to treat severe skin and skin structure infections caused by Gram-positive bacteria. Merck has also developed innovative technologies, such as its LipidRescue™ technology, which enhances the delivery of antibiotics to the site of infection. The company's strong research capabilities and commitment to developing new treatments for unmet medical needs make it a formidable competitor in the acute bacterial skin and skin structure infection market. Merck's global reach and extensive healthcare partnerships allow it to effectively distribute its products and reach a broad patient population. ### **Key Companies in the Acute Bacterial Skin and Skin Structure Infection Market Include:** ### **Acute Bacterial Skin Skin Structure Infection Market Industry Developments** - **Q2 2024: Melinta Therapeutics Announces FDA Approval of KIMYRSA® (oritavancin) for the Treatment of Acute Bacterial Skin and Skin Structure Infections** Melinta Therapeutics received FDA approval for KIMYRSA®, a single-dose intravenous antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI), expanding its portfolio of anti-infective therapies. ## **Acute Bacterial Skin and Skin Structure Infection Market Segmentation** ### **Acute Bacterial Skin and Skin Structure Infection Infection Type Outlook** ### **Acute Bacterial Skin and Skin Structure Infection Pathogen Outlook** ### **Acute Bacterial Skin and Skin Structure Infection Treatment Setting Outlook** ### **Acute Bacterial Skin and Skin Structure Infection Mechanism of Action Outlook** ### **Acute Bacterial Skin and Skin Structure Infection Route of Administration Outlook** ### **Acute Bacterial Skin and Skin Structure Infection Regional Outlook** ## Market Drivers ### 医疗支出上升 各地区医疗支出的上升趋势是急性细菌性皮肤及皮肤结构感染市场的关键驱动因素。对医疗基础设施和服务的投资增加，促进了人们更好地获得医疗护理，包括皮肤感染的治疗。随着医疗系统的扩展，先进治疗选项和技术的可用性提高，从而改善患者的治疗效果。此外，医疗支出的增加通常与对皮肤感染的意识和教育的提高相关，促使个人寻求及时的医疗干预。这一趋势可能会刺激市场增长，因为更多患者接受急性细菌性皮肤感染的治疗，从而推动对有效疗法和干预措施的需求。 ### 提高意识和教育 对皮肤感染及其潜在并发症的认识日益增强，这成为急性细菌性皮肤及皮肤结构感染市场的重要驱动力。医疗机构和政府部门的教育活动在告知公众有关皮肤感染的症状和风险方面发挥了重要作用。这种增强的意识鼓励个人及时寻求医疗帮助，从而提高急性细菌性皮肤感染的诊断率。随着更多患者被诊断，针对有效治疗方案的需求上升，可能导致市场增长的潜力。此外，医疗服务提供者可能会优先开发针对性疗法，这可能进一步增强急性细菌性皮肤及皮肤结构感染市场。 ### 诊断中的技术创新 诊断工具的技术进步正在改变急性细菌性皮肤及皮肤结构感染市场的格局。快速诊断测试和分子技术等创新使医疗专业人员能够更有效地识别细菌病原体。这种快速识别对于及时治疗至关重要，这可以显著改善患者的治疗结果。先进技术在临床环境中的整合可能会提高诊断的准确性，从而增加接受适当治疗的患者数量。随着诊断能力的提高，急性细菌性皮肤感染市场预计将扩大，推动这一市场发展的因素是对有效和及时干预的需求。 ### 皮肤病的发病率上升 皮肤病（如蜂窝组织炎和脓肿）的日益普遍是急性细菌性皮肤及皮肤结构感染市场的一个显著驱动因素。报告显示，皮肤感染占医疗就诊的相当大一部分，每年记录的病例数以百万计。这一增长可归因于多种因素，包括生活方式的变化、环境影响以及老龄化人口。随着这些感染发生率的上升，对有效治疗选择的需求也在加剧。因此，制药公司可能会加大对研发的投资，以创造创新疗法。这一趋势不仅突显了对有效管理皮肤感染的迫切需求，也强调了急性细菌性皮肤及皮肤结构感染市场的增长潜力。 ### 日益严重的抗生素耐药性 抗生素耐药性日益严重的问题对急性细菌性皮肤感染的管理构成了相当大的挑战，从而影响了急性细菌性皮肤及皮肤结构感染市场。随着细菌进化并对常用抗生素产生耐药性，医疗提供者被迫寻求替代治疗方案。这种情况导致对新型抗生素和替代疗法（如噬菌体疗法和免疫疗法）的开发越来越受到关注。解决抗生素耐药性的问题的紧迫性可能会推动研究和开发工作，从而导致市场的动态变化。因此，急性细菌性皮肤及皮肤结构感染市场可能会随着新治疗方式的出现而经历显著变化，以应对耐药菌株。 ## Future Outlook 急性细菌性皮肤及皮肤结构感染市场预计将在2024年至2035年间以4.44%的年均增长率增长，推动因素包括感染率上升和治疗选择的进步。 **New opportunities:** - 开发远程咨询和处方的远程医疗平台。 投资于快速诊断测试技术，以提高治疗效率。 扩展针对抗生素耐药性问题的靶向抗生素疗法。 到2035年，市场预计将实现强劲增长，反映出不断变化的医疗需求。 ## Segment Insights ### 按感染类型：蜂窝组织炎（最大）与脓肿（增长最快） 在急性细菌性皮肤和皮肤结构感染市场中，蜂窝组织炎占据了最大的市场份额，反映了其在各种人群和环境中的普遍性。紧随其后，丹毒和脓疱病也展现出显著的市场份额，而毛囊炎则相对不那么显著，但在更广泛的背景下仍然至关重要。尽管脓肿细分市场传统上不太占主导地位，但由于人们意识的提高和治疗选择的改善，正在迅速获得关注，创造了一个动态且竞争激烈的感染类型环境。 蜂窝组织炎（主导）与脓肿（新兴） 蜂窝组织炎以皮肤及其下层组织的炎症和感染为特征，仍然是急性细菌性皮肤及皮肤结构感染市场中占主导地位的感染类型。其流行程度受到多种因素的驱动，如受伤和潜在健康状况，使其成为医疗服务提供者的优先考虑对象。相反，脓肿正逐渐成为一个重要问题，特别是由于与抗生素耐药细菌相关的病例增加。脓肿病例的增加归因于更强大的诊断技术和更高的医疗服务可及性，鼓励患者更早寻求治疗。这种对蜂窝组织炎和脓肿的双重关注突显了在社区中管理细菌感染的复杂性。 ### 按病原体：金黄色葡萄球菌（最大）与化脓性链球菌（生长最快） 在急性细菌性皮肤和皮肤结构感染市场中，‘病原体’细分市场在各种病原体之间表现出多样的分布模式。金黄色葡萄球菌在市场中占据主导地位，由于其在皮肤感染中的普遍性，拥有显著的市场份额，而链球菌则迅速获得关注，成为该领域增长最快的病原体。其他显著的病原体包括铜绿假单胞菌、肠杆菌科和厌氧菌，它们对整体竞争格局也有贡献，尽管与前两者相比程度较轻。增长趋势表明，关注点正在转向识别和治疗由链球菌引起的感染，这一转变是由于皮肤感染发生率的上升以及医疗专业人员意识的提高。此外，针对性疗法的持续研究和进展可能会增强新兴病原体如铜绿假单胞菌和厌氧菌的市场地位，因为它们在临床环境中变得更加突出。这种病原体流行的多样化将影响未来在急性细菌性皮肤和皮肤结构感染市场中的感染管理和治疗策略。 金黄色葡萄球菌（主导）与化脓性链球菌（新兴） 金黄色葡萄球菌被认为是急性细菌性皮肤及皮肤结构感染市场的主要病原体，因其广泛存在和适应性强，使其成为全球皮肤相关感染的主要原因。它对多种抗生素的顽固抵抗使其成为研究和治疗创新的焦点。相比之下，链球菌（化脓性链球菌）是一个新兴病原体，因感染率上升和对其在皮肤及软组织感染中作用的认识增加而变得越来越重要。随着医疗提供者增强诊断能力和治疗方案，链球菌感染的上升趋势标志着临床关注的重大转变，迫切需要更新治疗方法，并促进对有效管理策略的持续研究。 ### 按治疗设置：门诊（最大）与急诊科（增长最快） 在急性细菌性皮肤和皮肤结构感染市场中，治疗环境细分在“门诊”、“住院”和“急诊科”类别之间存在差异化的份额。由于对居家医疗的日益偏好和住院时间的减少，门诊环境主导市场，成为最大的细分市场。同时，住院设施对于需要广泛医疗护理的重症病例仍然至关重要，在该市场中占据稳定的份额。然而，急诊科细分市场正在迅速增长，随着患者流入量的增加和处理急性感染的效率提升，推动了其扩展。 门诊（主导）与急诊科（新兴） 门诊环境已成为治疗急性细菌性皮肤及皮肤结构感染的主导力量，因为它们能够提供即时护理，同时减少长期住院的需求。该环境支持各种创新治疗方式和以患者为中心的护理。相反，急诊科被认为是一个新兴领域，其特点是为了应对急性感染的诊断增加而进行的重大调整。就诊人数的增加和更快的治疗方案促进了其市场份额的增长，推动了基础设施和人员配置的改善，以有效管理患者流动并提供及时护理。 ### 按作用机制：青霉素（最大）与头孢菌素（增长最快） 在急性细菌性皮肤和皮肤结构感染市场中，青霉素在各种作用机制中占据最大的市场份额。由于其对广谱细菌，特别是链球菌和葡萄球菌的有效性，它们长期以来一直被用于治疗皮肤感染。紧随其后的是头孢菌素，由于其对耐药菌株的日益使用以及与旧抗生素相比更高的安全性，它们展现出快速的增长轨迹。 青霉素（主导）与大环内酯（新兴） 青霉素在急性细菌性皮肤及皮肤结构感染市场中占主导地位，因其疗效确立且医生熟悉。它们特别受到青睐，因为能够应对广泛的革兰氏阳性细菌。相比之下，大环内酯类药物已成为一种重要的治疗选择，特别是对于对青霉素过敏的患者或需要替代疗法的患者。凭借其独特的机制，大环内酯类药物为治疗由非典型病原体引起的感染提供了重要选择，并随着对耐药菌株认识的提高而被越来越多地采用。 ### 按给药途径：静脉注射（最大）与局部用药（增长最快） 在急性细菌性皮肤和皮肤结构感染市场中，给药途径在治疗效果中起着至关重要的作用。静脉给药占据了最大的市场份额，表明在严重感染中对快速全身给药的偏好。口服给药紧随其后，通常因其便利性和易用性而受到青睐，而局部治疗则因其局部疗效而越来越受到认可。皮肤感染的发生率不断上升，使这些给药途径的相关性不断提高，每个细分市场都满足不同患者的需求。增长趋势表明市场正在发生变化，特别是局部治疗方法，因消费者对非侵入性疗法的偏好上升而成为增长最快的细分市场。推动这一趋势的因素包括对抗生素耐药性认识的提高和对靶向治疗选择的需求。随着医疗实践的发展，快速、有效和以患者为中心的给药途径的偏好预计将在未来几年更深刻地影响市场。 给药方法：静脉注射（主流）与局部用药（新兴） 静脉给药目前是治疗急性细菌性皮肤及皮肤结构感染的主要方法，尤其是在医院环境中。其在迅速将抗生素直接输送到血液中的有效性无与伦比，使其在管理严重病例时至关重要。另一方面，局部给药作为一种强有力的替代方案，因其使用方便和日益增长的居家护理趋势而受到关注。它允许对局部感染进行针对性治疗，并最小化全身副作用。这两种方法满足不同的治疗需求：静脉给药用于需要立即干预的严重病例，而局部给药则适用于便利性和患者舒适性至关重要的较轻症状。随着对这两种治疗方式的认识不断提高，这两个领域的使用率可能会增加。 ## Regional Market Share Analysis 全球急性细菌性皮肤及皮肤结构感染市场分为北美、欧洲、亚太、南美和中东及非洲。由于皮肤感染的高发病率和对先进治疗方案的日益采用，北美地区预计将占据最大的市场份额。 欧洲地区也预计将对市场增长做出显著贡献，主要受老年人口增加和对先进伤口护理产品需求上升的推动。亚太地区预计将见证最快的增长率，原因是医疗支出增加和对皮肤感染的认识不断提高。 南美和中东及非洲地区也预计将对市场增长做出贡献，尽管增速较慢。 来源：初步研究、二次研究、_市场研究未来_数据库及分析师评审 ## Competitive Benchmarking 急性细菌性皮肤及皮肤结构感染市场的主要参与者不断进行研究和开发活动，以增强其产品供应并获得竞争优势。战略合作与伙伴关系也很普遍，因为公司寻求扩大其地理覆盖范围并进入新市场。 急性细菌性皮肤及皮肤结构感染市场的特点是参与者多样，包括跨国制药公司、仿制药制造商和专注于皮肤病学的专业制药公司。 领先的急性细菌性皮肤及皮肤结构感染市场参与者正在投资创新技术，如新型药物递送系统和靶向疗法，以满足未满足的医疗需求并改善患者结果。 急性细菌性皮肤及皮肤结构感染市场的发展管道强劲，多个有前景的候选药物处于不同的临床开发阶段。这些进展预计将进一步塑造竞争格局，并推动未来几年的市场增长。 辉瑞是急性细菌性皮肤及皮肤结构感染市场的领先参与者，拥有强大的抗生素产品组合，包括广泛用于治疗细菌性皮肤感染的Zithromax和Vibramycin。该公司对研究和开发的关注导致了新抗生素的开发，如Sivextro，已证明对广谱细菌有效。 辉瑞的全球存在和强大的分销网络使其能够接触到广泛的患者和医疗提供者。该公司对创新和患者护理的承诺使其在急性细菌性皮肤及皮肤结构感染市场中保持领导地位。 默克是一家全球制药公司，也是急性细菌性皮肤及皮肤结构感染市场的另一主要竞争者。该公司的抗生素产品组合包括Cubicin，用于治疗由革兰阳性细菌引起的严重皮肤及皮肤结构感染。 默克还开发了创新技术，如其LipidRescue™技术，增强了抗生素到达感染部位的递送。该公司强大的研究能力和对开发满足未满足医疗需求的新治疗的承诺使其成为急性细菌性皮肤及皮肤结构感染市场的强大竞争者。 默克的全球覆盖和广泛的医疗合作伙伴关系使其能够有效分销其产品并接触到广泛的患者群体。 ## Recent News & Developments - **2024年第二季度：Melinta Therapeutics宣布KIMYRSA®（奥利达星）获得FDA批准，用于治疗急性细菌性皮肤和皮肤结构感染** Melinta Therapeutics获得了KIMYRSA®的FDA批准，这是一种用于治疗急性细菌性皮肤和皮肤结构感染（ABSSSI）的单剂量静脉注射抗生素，扩展了其抗感染治疗产品组合。 ## Report Scope | 2024年市场规模 | 70.06（十亿美元） | | --- | --- | | 2025年市场规模 | 73.18（十亿美元） | | 2035年市场规模 | 113（十亿美元） | | 复合年增长率（CAGR） | 4.44%（2024 - 2035） | | 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 | | 基准年 | 2024 | | 市场预测期 | 2025 - 2035 | | 历史数据 | 2019 - 2024 | | 市场预测单位 | 十亿美元 | | 主要公司简介 | 市场分析进行中 | | 覆盖的细分市场 | 市场细分分析进行中 | | 主要市场机会 | 针对性疗法和诊断的进步提高了急性细菌性皮肤及皮肤结构感染市场的治疗效果。 | | 主要市场动态 | 抗生素耐药性上升推动了急性细菌性皮肤及皮肤结构感染治疗选择的创新。 | | 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 | ## Frequently Asked Questions **Q: 急性细菌性皮肤及皮肤结构感染市场的当前市场估值是多少？** A: 截至2024年，市场估值为70.06亿美元。 **Q: 到2035年，急性细菌性皮肤及皮肤结构感染市场的预计市场规模是多少？** A: 预计到2035年，市场估值将达到113亿美元。 **Q: 在预测期内，急性细菌性皮肤及皮肤结构感染市场的预期CAGR是多少？** A: 预计市场在2025年至2035年间的年均增长率（CAGR）为4.44%。 **Q: 在急性细菌性皮肤及皮肤结构感染领域，哪些感染类型在市场估值中处于领先地位？** A: 到2035年，蜂窝组织炎和脓疱病分别以34亿美元和24亿美元的估值位居前列。 **Q: 导致急性细菌性皮肤及皮肤结构感染市场的主要病原体有哪些？** A: 金黄色葡萄球菌和化脓性链球菌是重要的贡献者，预计到2035年，估值分别为34亿美元和24亿美元。 **Q: 治疗环境如何影响急性细菌性皮肤及皮肤结构感染的市场估值？** A: 预计住院治疗环境将占主导地位，预计到2035年估值将达到40亿美元。 **Q: 急性细菌性皮肤及皮肤结构感染市场治疗的主要作用机制是什么？** A: 青霉素和氟喹诺酮预计将领先，预计到2035年估值分别为24亿美元和26亿美元。 **Q: 在急性细菌性皮肤及皮肤结构感染市场中，最常见的给药途径有哪些？** A: 口服和静脉给药途径预计将占主导地位，预计到2035年分别达到34亿美元和40亿美元的估值。 --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/acute-bacterial-skin-skin-structure-infection-market-31211*